BioWorld

March 30, 2004

Amgen Gets Even Stronger With $1.3B Tularik Acquisition

In one of the largest biotech deals this year, Amgen Inc. caught the big fish, so to speak, by reeling in Tularik Inc. with a $1.3 billion takeover bid. (BioWorld Today) Read More

Kemia Raises $33.5M In Series B For Work In Kinase Inhibitors

OxiGene Shares Get A Boost From Preclinical Cancer Data

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 14, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...